Palbociclib Capsules 125mg
PALBOLIEVA 125 MG (Palbociclib Capsules 125 mg) is a prescription targeted anticancer medicine containing Palbociclib 125 mg, an advanced CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used primarily for the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed as part of combination therapy with hormonal treatments to help slow cancer growth and improve treatment outcomes.
Breast cancer is one of the most common cancers affecting women worldwide. Certain breast cancers depend on hormones such as estrogen and progesterone for growth. In these cancers, abnormal cell cycle activity can cause uncontrolled tumor growth and disease progression. PALBOLIEVA 125 MG works by targeting proteins known as CDK4 and CDK6, which play a critical role in cell division and cancer cell proliferation.
By blocking these proteins, Palbociclib helps stop cancer cells from progressing through the cell cycle, thereby slowing tumor growth and delaying disease progression. This targeted mechanism has transformed the treatment landscape for HR-positive, HER2-negative advanced breast cancer and has become a standard component of modern oncology care.
Unlike conventional chemotherapy, Palbociclib specifically targets cancer growth pathways while working alongside hormone therapies such as aromatase inhibitors or fulvestrant. This precision-based approach allows for more effective disease control while helping maintain quality of life.
PALBOLIEVA 125 MG is commonly prescribed for:
HR-Positive, HER2-Negative Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Recurrent Breast Cancer
Hormone Receptor-Positive Breast Cancer
Combination Endocrine Therapy Programs
Targeted Oncology Treatment Plans
Long-Term Breast Cancer Management
The medicine is typically prescribed after careful evaluation by an oncologist and may be used in different stages of advanced breast cancer treatment depending on the patient's medical condition and treatment history.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 125 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function tests, infection assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 125 MG has become an important treatment option in modern breast cancer management worldwide.
View Details
Palbolieva Capsules 100mg
PALBOLIEVA 100 MG (Palbociclib Capsules 100 mg) is a prescription targeted anticancer medicine containing Palbociclib 100 mg, a highly effective CDK4/6 (Cyclin-Dependent Kinase 4 and 6) inhibitor used in the treatment of Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer. It is commonly prescribed in combination with hormone therapies to help slow cancer progression, control tumor growth, and improve patient outcomes.
Breast cancer remains one of the most frequently diagnosed cancers worldwide. Many breast cancer cells rely on hormones such as estrogen for growth and survival. In HR-positive breast cancer, abnormal activation of cellular pathways can cause uncontrolled cell division and tumor progression. PALBOLIEVA 100 MG is specifically designed to target these pathways by blocking CDK4 and CDK6 proteins, which are essential for cancer cell multiplication.
By preventing cancer cells from progressing through critical stages of the cell cycle, Palbociclib helps reduce tumor growth and delay disease progression. This targeted mechanism has significantly improved treatment strategies for patients with advanced and metastatic hormone receptor-positive breast cancer.
Unlike traditional chemotherapy, which affects rapidly dividing healthy and cancerous cells alike, Palbociclib offers a more precise approach by targeting specific proteins involved in cancer cell proliferation. This allows it to work effectively alongside endocrine therapies such as aromatase inhibitors and fulvestrant.
PALBOLIEVA 100 MG is commonly prescribed for:
HR-Positive, HER2-Negative Advanced Breast Cancer
Metastatic Breast Cancer
Locally Advanced Breast Cancer
Recurrent Breast Cancer
Hormone Receptor-Positive Breast Cancer
Combination Endocrine Therapy Programs
Targeted Oncology Treatment Plans
Long-Term Breast Cancer Management
The medicine is often used as part of personalized treatment strategies developed by oncologists based on the patient’s cancer stage, medical history, and treatment goals.
Manufactured under stringent pharmaceutical quality standards, PALBOLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Palbociclib therapy require regular monitoring, including complete blood counts, liver function assessments, infection evaluations, and routine clinical examinations to ensure safe and effective treatment.
Due to its proven efficacy and targeted mechanism of action, PALBOLIEVA 100 MG has become an important treatment option in modern breast cancer care worldwide.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription anticancer medicine containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically designed to help slow the growth and spread of prostate cancer cells by blocking the effects of male hormones, known as androgens, that fuel cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers in men worldwide. Many prostate cancer cells depend on testosterone and other androgens for survival and growth. Even after treatments that lower testosterone levels, cancer cells may continue to grow by activating androgen receptors. ENZALIEVA 40 MG helps overcome this challenge by directly blocking androgen receptor signaling, thereby reducing the ability of cancer cells to multiply and spread.
Enzalutamide belongs to a class of medicines known as Androgen Receptor Inhibitors. Unlike conventional hormone therapies that primarily reduce testosterone production, Enzalutamide works by preventing androgen receptors from receiving hormonal signals. This dual approach helps provide more effective disease control in advanced stages of prostate cancer.
ENZALIEVA 40 MG is commonly prescribed for:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Long-Term Prostate Cancer Management
Hormone-Driven Prostate Tumors
Precision Oncology Treatment Programs
The medicine may be used as part of a comprehensive cancer treatment plan developed by an oncologist based on the patient's medical condition, disease stage, and treatment history.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Enzalutamide therapy typically require regular monitoring, including blood pressure assessments, liver function evaluations, neurological monitoring, and routine clinical follow-up to ensure safe and effective treatment.
Due to its targeted mechanism of action and proven clinical benefits, ENZALIEVA 40 MG has become an important treatment option in modern prostate cancer care worldwide.
View Details
Enzalutamide Capsules 40mg
ENZALIEVA 40 MG (Enzalutamide Capsules 40 mg) is a prescription medication containing Enzalutamide 40 mg, a next-generation androgen receptor inhibitor used for the treatment of advanced prostate cancer. It is specifically developed to help control the growth and spread of prostate cancer cells by blocking the effects of male hormones (androgens) that play a crucial role in cancer progression.
Prostate cancer is one of the most commonly diagnosed cancers among men worldwide. While many prostate cancers initially respond to hormone-lowering therapies, some cancers eventually continue to grow despite reduced testosterone levels. ENZALIEVA 40 MG helps address this challenge by directly targeting androgen receptor signaling pathways that cancer cells rely on for survival and multiplication.
Enzalutamide works differently from traditional hormone therapies. Instead of only reducing hormone production, it blocks the androgen receptor at multiple stages, preventing cancer cells from receiving and using hormonal signals. This advanced mechanism helps slow tumor growth, delay disease progression, and support long-term disease management.
ENZALIEVA 40 MG is widely prescribed for patients with:
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Advanced Prostate Cancer
Recurrent Prostate Cancer
Hormone-Driven Prostate Tumors
Long-Term Prostate Cancer Management
Precision Oncology Treatment Programs
The medicine has become an important part of modern prostate cancer treatment because of its proven ability to improve progression-free survival and help maintain quality of life in eligible patients.
Unlike conventional chemotherapy, ENZALIEVA 40 MG specifically targets pathways involved in prostate cancer growth, making it a highly effective option for selected patients. It is often prescribed as part of a comprehensive oncology treatment plan under the supervision of experienced healthcare professionals.
Manufactured according to stringent pharmaceutical quality standards, ENZALIEVA 40 MG is designed to deliver consistent therapeutic performance, safety, and reliability.
Regular follow-up appointments, laboratory testing, and clinical evaluations are important during treatment to monitor effectiveness and manage any potential side effects.
View Details
Olaparib Tablets 150mg
PARIBLIEVA 150 MG (Olaparib Tablets 150 mg) is a prescription targeted anticancer medicine containing Olaparib 150 mg, a highly advanced PARP (Poly ADP-Ribose Polymerase) inhibitor used in the treatment of several types of cancer associated with specific genetic mutations, particularly BRCA1 and BRCA2 mutations. Olaparib is widely used in modern precision oncology to help slow cancer growth, delay disease progression, and improve treatment outcomes in eligible patients.
Cancer cells with BRCA gene mutations often have difficulty repairing damaged DNA. PARIBLIEVA 150 MG works by blocking PARP enzymes, which cancer cells use to repair their DNA. When both repair mechanisms are disrupted, cancer cells are unable to survive and eventually die. This targeted approach allows Olaparib to selectively attack cancer cells while minimizing damage to healthy tissues.
PARIBLIEVA 150 MG has become an important treatment option in personalized cancer care and is commonly prescribed for patients whose tumors carry specific genetic abnormalities. Genetic testing is often performed before treatment to determine whether a patient is likely to benefit from Olaparib therapy.
Unlike conventional chemotherapy, which affects rapidly dividing cells throughout the body, Olaparib specifically targets cancer cells with defective DNA repair pathways. This precision-based mechanism has transformed the treatment landscape for several difficult-to-treat cancers.
PARIBLIEVA 150 MG is commonly prescribed for:
BRCA-Mutated Ovarian Cancer
Advanced Ovarian Cancer
Recurrent Ovarian Cancer
BRCA-Mutated Breast Cancer
HER2-Negative Breast Cancer with BRCA Mutation
Metastatic Breast Cancer
Pancreatic Cancer with BRCA Mutation
Metastatic Pancreatic Cancer
Prostate Cancer with Homologous Recombination Repair (HRR) Gene Mutations
Precision Oncology Treatment Programs
The medicine may be used as maintenance therapy after successful cancer treatment or as part of long-term disease management plans, depending on the patient's condition and oncologist’s recommendations.
Manufactured according to stringent pharmaceutical quality standards, PARIBLIEVA 150 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Olaparib therapy require routine monitoring, including blood tests, kidney and liver function assessments, and regular clinical evaluations to ensure safe and effective treatment.
Due to its targeted mechanism and proven clinical benefits, PARIBLIEVA 150 MG has become a valuable treatment option in modern cancer care worldwide.
View Details
Lenvatinib Capsules 10mg
LENVALIEVA 10 MG (Lenvatinib Capsules 10 mg) is a prescription targeted anticancer medicine containing Lenvatinib 10 mg, an advanced multi-kinase inhibitor used for the treatment of several types of cancer. It is commonly prescribed for patients with thyroid cancer, liver cancer, kidney cancer, and endometrial cancer, helping to slow tumor growth, delay disease progression, and improve treatment outcomes.
Lenvatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs). It works by blocking specific proteins involved in tumor growth and blood vessel formation. Cancer cells require a continuous blood supply to receive oxygen and nutrients needed for growth. LENVALIEVA 10 MG helps prevent the formation of new blood vessels that feed tumors, thereby limiting cancer progression.
Unlike conventional chemotherapy, which attacks rapidly dividing cells throughout the body, Lenvatinib specifically targets pathways involved in cancer growth and angiogenesis (blood vessel formation). This targeted approach has made it an important component of modern oncology treatment strategies.
LENVALIEVA 10 MG is commonly prescribed for:
Differentiated Thyroid Cancer (DTC)
Radioactive Iodine-Refractory Thyroid Cancer
Hepatocellular Carcinoma (Liver Cancer)
Advanced Renal Cell Carcinoma (Kidney Cancer)
Advanced Endometrial Cancer
Metastatic Solid Tumors (Selected Cases)
Targeted Oncology Treatment Programs
Long-Term Cancer Management
The medicine may be used alone or in combination with other anticancer therapies depending on the patient's diagnosis, disease stage, and treatment goals.
Lenvatinib has become a valuable treatment option because it targets multiple pathways involved in cancer progression, helping improve disease control in patients with advanced cancers.
Manufactured according to stringent pharmaceutical quality standards, LENVALIEVA 10 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenvatinib therapy require routine medical monitoring, including blood pressure assessments, liver function tests, kidney function evaluations, thyroid monitoring, and regular clinical examinations.
Due to its targeted mechanism and broad clinical applications, LENVALIEVA 10 MG plays an important role in modern cancer care worldwide.
View Details
Lenvatinib Capsules 4mg
LENVALIEVA 4 mg contains Lenvatinib, an oral multi-targeted tyrosine kinase inhibitor (TKI). It inhibits multiple receptors involved in tumor growth and angiogenesis, including VEGFR 1–3, FGFR 1–4, PDGFR-α, RET, and KIT, thereby suppressing tumor vascularization and proliferation.
View Details
Eltrombopag Olamine Tablets 50mg
TROMLIEVA 50 MG (Eltrombopag Olamine Tablets 50 mg) is a prescription medicine containing Eltrombopag Olamine 50 mg, a thrombopoietin receptor agonist used to increase platelet production in patients with certain blood disorders. It is commonly prescribed for individuals with chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with chronic hepatitis C under the supervision of a qualified healthcare professional.
Platelets are blood cells that play a vital role in blood clotting and preventing excessive bleeding. When platelet levels become too low, patients may experience symptoms such as easy bruising, prolonged bleeding, frequent nosebleeds, bleeding gums, or tiny red spots on the skin known as petechiae. TROMLIEVA 50 MG helps address this problem by stimulating the body’s natural platelet production process.
Eltrombopag works by activating thrombopoietin receptors located in the bone marrow. These receptors are responsible for signaling the production of platelets. By stimulating these receptors, TROMLIEVA 50 MG helps increase platelet counts and reduce the risk of bleeding complications.
Unlike platelet transfusions, which provide a temporary increase in platelet levels, Eltrombopag encourages the body to produce its own platelets, making it a valuable option for long-term management in eligible patients.
TROMLIEVA 50 MG is commonly prescribed for:
Chronic Immune Thrombocytopenia (ITP)
Severe Aplastic Anemia
Low Platelet Counts Due to Chronic Hepatitis C
Bone Marrow Failure Disorders
Platelet Support During Treatment Programs
Long-Term Management of Thrombocytopenia
Hematology Treatment Protocols
Blood Disorder Management Programs
The medicine is often recommended when other treatments have not provided adequate platelet improvement or when long-term platelet support is required.
Manufactured according to stringent pharmaceutical quality standards, TROMLIEVA 50 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Eltrombopag therapy typically require routine blood tests, platelet count monitoring, liver function assessments, and regular medical evaluations to ensure safe and effective treatment.
Due to its proven ability to increase platelet production, TROMLIEVA 50 MG has become an important treatment option in modern hematology care.
View Details
Eltrombopag Olamine Tablets 25mg
TROMLIEVA 25 MG (Eltrombopag Olamine Tablets 25 mg) is a prescription medicine containing Eltrombopag Olamine 25 mg, a thrombopoietin receptor agonist used to increase platelet production in patients suffering from certain blood disorders associated with low platelet counts. It is commonly prescribed for the treatment of Chronic Immune Thrombocytopenia (ITP), Severe Aplastic Anemia, and thrombocytopenia associated with chronic hepatitis C infection.
Platelets are essential blood components that help the body form clots and prevent excessive bleeding. When platelet levels become abnormally low, patients may experience symptoms such as easy bruising, prolonged bleeding, nosebleeds, bleeding gums, fatigue, and the appearance of tiny red or purple spots on the skin. TROMLIEVA 25 MG helps stimulate the body's natural platelet production process, reducing the risk of bleeding complications.
Eltrombopag works by activating thrombopoietin receptors found in the bone marrow. These receptors play a key role in the production of platelets. By stimulating these receptors, TROMLIEVA 25 MG encourages the bone marrow to produce more platelets, helping restore healthier platelet levels in the bloodstream.
Unlike platelet transfusions that provide only temporary support, Eltrombopag promotes sustained platelet production by the body's own cells, making it an effective long-term treatment option for many eligible patients.
TROMLIEVA 25 MG is commonly prescribed for:
Chronic Immune Thrombocytopenia (ITP)
Severe Aplastic Anemia (SAA)
Hepatitis C-Associated Thrombocytopenia
Bone Marrow Failure Disorders
Platelet Production Support Therapy
Long-Term Management of Low Platelet Counts
Hematology Treatment Programs
Blood Disorder Management
The medicine may be prescribed when conventional therapies have failed to provide adequate improvement in platelet counts or when long-term platelet management is required.
Manufactured under stringent pharmaceutical quality standards, TROMLIEVA 25 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Eltrombopag therapy typically require regular blood tests, platelet monitoring, liver function assessments, and routine clinical evaluations to ensure safe and effective treatment.
Due to its proven ability to stimulate platelet production, TROMLIEVA 25 MG has become an important therapeutic option in modern hematology practice.
View Details
Temozolomide Capsules IP 250mg
TEMALIEVA 250 MG (Temozolomide Capsules IP 250 mg) is a prescription anticancer medicine containing Temozolomide 250 mg, an oral chemotherapy agent used primarily for the treatment of certain types of brain tumors. It belongs to a class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells, preventing them from growing and multiplying.
Brain tumors can be aggressive and difficult to treat due to their location and complex nature. Temozolomide has become an important component of modern neuro-oncology treatment because of its ability to cross the blood-brain barrier and directly target tumor cells within the brain. This unique characteristic makes it particularly effective in the management of specific malignant brain tumors.
TEMALIEVA 250 MG is commonly prescribed for patients diagnosed with Glioblastoma Multiforme (GBM), one of the most aggressive forms of brain cancer, and Anaplastic Astrocytoma, a malignant brain tumor arising from astrocyte cells. It may be used alone or in combination with radiation therapy and other treatment modalities as part of a comprehensive cancer management plan.
Unlike many traditional chemotherapy medicines that require intravenous administration, Temozolomide is available in capsule form, offering greater convenience and flexibility for patients undergoing long-term treatment.
The medicine is often prescribed during both initial treatment and maintenance therapy phases, depending on the patient’s diagnosis, treatment response, and oncologist's recommendations.
TEMALIEVA 250 MG is commonly used for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 250 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Temozolomide therapy require regular blood tests, complete blood count monitoring, liver function assessments, and clinical evaluations to ensure safe and effective treatment.
Due to its proven efficacy in brain cancer treatment, TEMALIEVA 250 MG has become a trusted option in modern oncology and neuro-oncology care worldwide.
View Details
Temozolomide Capsules IP 100 mg
TEMALIEVA 100 MG (Temozolomide Capsules IP 100 mg) is a prescription anticancer medicine containing Temozolomide 100 mg, an oral chemotherapy drug widely used in the treatment of certain malignant brain tumors. It belongs to a class of medicines known as alkylating agents, which work by interfering with the DNA of cancer cells, preventing them from growing, multiplying, and spreading.
Brain tumors are among the most complex cancers to treat due to their location within the central nervous system. One of the major advantages of Temozolomide is its ability to cross the blood-brain barrier, allowing it to directly target cancer cells within the brain. This characteristic has made Temozolomide a cornerstone treatment in modern neuro-oncology.
TEMALIEVA 100 MG is commonly prescribed for patients diagnosed with Glioblastoma Multiforme (GBM), the most aggressive type of primary brain cancer, and Anaplastic Astrocytoma, a high-grade malignant brain tumor. It may be used as part of initial treatment, maintenance therapy, or recurrent tumor management depending on the patient's condition and oncologist's recommendations.
Unlike many traditional chemotherapy medicines that require intravenous administration, TEMALIEVA 100 MG is available in capsule form, making treatment more convenient for eligible patients while supporting long-term cancer management.
Temozolomide has become an important component of comprehensive brain cancer treatment programs because it can be used alone or alongside radiation therapy to improve disease control and treatment outcomes.
TEMALIEVA 100 MG is commonly prescribed for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Temozolomide therapy require regular medical supervision, including complete blood count monitoring, liver function assessments, infection screening, and clinical evaluations to ensure safe and effective treatment.
Due to its proven effectiveness in brain tumor management, TEMALIEVA 100 MG has become a trusted treatment option in oncology centers worldwide.
View Details
Temozolomide Capsules IP 20mg
TEMALIEVA 20 MG (Temozolomide Capsules IP 20 mg) is a prescription anticancer medicine containing Temozolomide 20 mg, an oral chemotherapy agent used in the treatment of specific malignant brain tumors. Temozolomide belongs to the class of medicines known as alkylating agents, which work by damaging the DNA of cancer cells and preventing them from growing, multiplying, and spreading.
Temozolomide is widely recognized in neuro-oncology because of its unique ability to cross the blood-brain barrier, enabling it to reach and act directly on tumor cells within the brain. This characteristic makes it an important treatment option for patients with aggressive and difficult-to-treat brain cancers.
TEMALIEVA 20 MG is commonly prescribed for the treatment of Glioblastoma Multiforme (GBM), the most aggressive form of primary brain cancer, and Anaplastic Astrocytoma, a high-grade malignant brain tumor. It may be used during initial treatment, maintenance therapy, or management of recurrent disease based on the patient’s condition and oncologist’s recommendations.
The 20 mg strength is often used as part of individualized dosing regimens, allowing oncologists to accurately adjust doses according to body surface area (BSA), treatment cycles, and patient-specific requirements.
Unlike intravenous chemotherapy, TEMALIEVA 20 MG is administered orally, providing convenience and flexibility while supporting long-term cancer treatment plans.
TEMALIEVA 20 MG is commonly used for:
Glioblastoma Multiforme (GBM)
Newly Diagnosed Glioblastoma
Recurrent Glioblastoma
Anaplastic Astrocytoma
Malignant Brain Tumors
Central Nervous System (CNS) Tumors
Maintenance Chemotherapy Programs
Neuro-Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, TEMALIEVA 20 MG is designed to ensure consistent quality, safety, and therapeutic effectiveness.
Patients undergoing Temozolomide treatment require regular blood count monitoring, liver function testing, and clinical evaluations to ensure safe and effective therapy.
Due to its established role in brain tumor treatment, TEMALIEVA 20 MG remains a valuable option in modern oncology and neuro-oncology care.
View Details
